World's Best Scientists 2026 revealed!

Robert A. Nathan publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Robert A. Nathan sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

The last bar groups every scientist with 807 publications or more.

Robert A. Nathan D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Robert A. Nathan sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

The last bar groups every scientist with 157 D-Index or more.

Overview

Robert A. Nathan is affiliated with the University of Colorado Colorado Springs in the United States. Their research primarily centers on pulmonary and respiratory medicine, with a focus on asthma and respiratory diseases.

Their recent publications cover various aspects of asthma treatment and respiratory drug delivery. Notable papers include the 2020 study "Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial" published in The Lancet Respiratory Medicine and the 2024 article "Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study" in The Journal of Allergy and Clinical Immunology In Practice.

Additional research articles comprise:

  • "A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids" (2020, Respiratory Research)
  • "Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy" (2020, The Journal of Allergy and Clinical Immunology In Practice)
  • "Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study" (2020, Journal of Allergy and Clinical Immunology)

Their frequent co-authors include Nicola A. Hanania, Edward Kerwin, Huib A.M. Kerstjens, Zelie Bailes, and Louis-Philippe Boulet.

Robert A. Nathan has published multiple papers in several notable journals, such as:

  • CHEST Journal
  • The Journal of Allergy and Clinical Immunology In Practice
  • Journal of Allergy and Clinical Immunology
  • The Lancet Respiratory Medicine
  • Respiratory Research

Their scientific work predominantly addresses the following research topics:

  • Asthma and respiratory diseases
  • Respiratory and cough-related research
  • Inhalation and respiratory drug delivery
  • Chronic obstructive pulmonary disease (COPD) research

The fields of study connected to Robert A. Nathan's output are medicine broadly, with a focus on pulmonary and respiratory medicine as well as physiology.

In addition to research articles, Robert A. Nathan has contributed to book publications, including "They went on together" (2020), published by the Japan Society of Medical Entomology and Zoology.

Best Publications

  • Development of the asthma control test: A survey for assessing asthma control

    Robert A Nathan;Christine A Sorkness;Mark Kosinski;Michael Schatz

  • Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists

    Michael Schatz;Christine A. Sorkness;James T. Li;Philip Marcus

  • The burden of allergic rhinitis.

    Robert A Nathan

  • The diagnosis and management of sinusitis: A practice parameter update

    Raymond G. Slavin;Sheldon L. Spector;I. Leonard Bernstein;Michael A. Kaliner

  • Prevalence of allergic rhinitis in the United States

    Robert A. Nathan;Eli O. Meltzer;John C. Seiner;William Storms

  • Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

    Hilary Longhurst;Marco Cicardi;Timothy Craig;Konrad Bork

  • Growth in asthmatic children treated with fluticasone propionate

    David B. Allen;Edwin A. Bronsky;Craig F. LaForce;Robert A. Nathan

  • Objective monitoring of nasal patency and nasal physiology in rhinitis

    Robert A. Nathan;Ron Eccles;Peter H. Howarth;Sverre K. Steinsvåg

  • Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey.

    Eli O. Meltzer;Robert Nathan;Jennifer Derebery;Paul E. Stang

  • The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey.

    Robert A. Nathan;Eli O. Meltzer;Jennifer Derebery;Ulka B. Campbell

  • Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.

    Laurie A Lee;Zelie Bailes;Neil Barnes;Louis-Philippe Boulet

  • Efficacy and Safety of Fexofenadine Hydrochloride for Treatment of Seasonal Allergic Rhinitis

    David I Bernstein;William F Schoenwetter;Robert A Nathan;William Storms

  • Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis.

    Eli O. Meltzer;Thomas B. Casale;Robert A. Nathan;Ann K. Thompson

  • Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey.

    Kevin R. Murphy;Eli O. Meltzer;Michael S. Blaiss;Robert A. Nathan

  • Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires

    Eli O. Meltzer;Robert A. Nathan;John C. Seiner;William Storms

  • The economic impact of allergic rhinitis

    William Storms;Eli O. Meltzer;Robert A. Nathan;John C. Selner

  • Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction

    R. A. Nathan;J. A. Bernstein;L. Bielory;C. M. Bonuccelli

  • Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control.

    Robert A. Nathan;Steven W. Yancey;Kelli Waitkus-Edwards;Barbara A. Prillaman

  • Psychometric validation of the rhinitis control assessment test: a brief patient-completed instrument for evaluating rhinitis symptom control.

    Michael Schatz;Eli O. Meltzer;Robert Nathan;M. Jennifer Derebery

  • Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis.

    Nathan Ra;Bronsky Ea;Fireman P;Grossman J

Frequent Co-Authors

Eli O. Meltzer
Eli O. Meltzer University of California, Berkeley
David I. Bernstein
David I. Bernstein University of Cincinnati
Michael Schatz
Michael Schatz Kaiser Permanente
Ian D. Pavord
Ian D. Pavord University of Oxford
Harold S. Nelson
Harold S. Nelson National Jewish Health
William W. Busse
William W. Busse University of Wisconsin–Madison
Jun-Tao Li
Jun-Tao Li Xiamen University
Bruce L. Zuraw
Bruce L. Zuraw University of California, San Diego
Jay M. Portnoy
Jay M. Portnoy University of Missouri–Kansas City

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology and seeking flexible education options, several online nursing degrees can complement this field. Many students begin with online ADN programs for non nurses, which offer a streamlined path for newcomers looking to enter healthcare and build foundational knowledge.

Once in nursing, professionals often explore advanced roles through accelerated RN to NP programs, enabling them to quickly transition into nurse practitioner roles that can interact closely with immunological research or patient care.

Specializing is another crucial step. For instance, the transition from family nurse practitioner (FNP) to acute care nurse practitioner (ACNP) can offer deeper expertise in critical care settings, which is often important when working with complex immunological conditions. Guidance on this shift can be found in the article about FNP to ACNP.

Career-wise, understanding which specialties are most lucrative is valuable. Immunology-related advanced nursing roles often align with some of the highest paid DNP specialties, highlighting a strong financial incentive alongside professional fulfillment.

Best Scientists Citing Robert A. Nathan

Trending Scientists